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Abstract
Objectives: This report examines the sociodemographic and
substance use characteristics, co-occurring psychological
status, substance abuse consequences, and prior experiences
with substance abuse treatment among patients with
cocaine-associated chest pain presenting to an emergency
department chest pain observation unit. Methods: This
was a consecutive cohort of patients in the emergency
department chest pain observation unit aged 18–60 years
with low to moderate risk for acute coronary syndrome and
recent cocaine use. Responses on standardized and vali-
dated instruments were used to examine demographic and
clinical characteristics of the sample and to compare
patients who met Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV) criteria for past
three-month substance abuse or substance dependence with
patients who did not. Results: Of 145 eligible patients
identified between June 1, 2002, and February 29, 2004, 86%
met criteria for a lifetime DSM-IV substance use disorder
and 50% met past three-month criteria. Approximately one
half of the total sample reported substantial symptoms of
depression. Substance use frequency and consequences,
depression, and psychological distress were significantly
more severe among those with past three-month substance
use diagnoses; however, most sociodemographic character-
istics were not associated with substance use diagnoses.
Interest in treatment services and treatment history was also
significantly associated with the presence of a substance
use disorder diagnosis. Conclusions: Findings regarding
diversity in alcohol and drug involvement, current level of
psychological functioning, depressive symptomatology, and
interest in treatment services provide useful information for
designing emergency department–based interventions for
this population. Key words: cocaine; chest pain; emergency
department; demography; substance-related disorders;
behavioral symptoms. ACADEMIC EMERGENCY MEDI-
CINE 2005; 12:329–337.
Cocaine is the most common illicit drug of abuse in
patients who present to the emergency department
(ED), and cocaine-related ED cases have increased
47% from 1995 to 2002.1 Correspondingly, as cocaine
use has become more widespread, the number of
cocaine-related cardiovascular events has increased.
Chest pain, whether cardiac or noncardiac, is the most
frequently reported consequence of cocaine abuse in
the ED2 and is highly prevalent in urban, inner-city
EDs.3,4 Associated with this increased use of cocaine
is the evaluation of more than 64,000 cocaine-using
patients annually for possible myocardial ischemia
at an annual cost in 1995 dollars of more than $83
million.5
The cardiovascular consequences of cocaine use
are cogently described. The risk of acute myocardial
infarction (AMI) is increased 24-fold in the hour after
cocaine use,6 and up to 6% of patients who present
to the ED with cocaine-induced chest pain sustain an
AMI.4,5 In addition, cocaine accounts for up to 25% of
AMIs in patients 18–45 years of age, and users have
a lifetime risk of nonfatal AMI that is seven times the
risk of nonusers.7 Numerous factors have been impli-
cated in the pathophysiology of cocaine-associated
myocardial ischemia, including coronary artery
vasoconstriction,8 platelet aggregation,9–12 in situ
thrombus formation,13–16 and premature atheroscle-
rosis.10,15,17,18 However, the relative contributions of
each of these mechanisms have not been widely
investigated and are poorly understood.
Even less is known about the clinical picture of
cocaine users presenting to the ED with chest pain in
terms of their overall substance use, their severity of
substance use, and their interest in treatment. Previous
studies have focused on individuals with substance
abuse and concomitant trauma and injuries.19,20 In
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addition, previous research has established that psy-
chiatric disorders are common comorbid conditions
among cocaine abusers in substance abuse treatment.21
However, there is a paucity of literature regarding
psychiatric disorders and other sociodemographic and
psychosocial characteristics among cocaine users who
are not in treatment who present to the ED with chest
pain.
The majority of patients with cocaine-associated
chest pain who are at low to moderate risk for cardiac
complications can be treated in ED chest pain obser-
vation units (CPOUs), and the safety and feasibility of
treatment protocols for these patients in CPOUs have
been previously demonstrated.22 We present a unique
and comprehensive characterization of the substance
use, mental health, and treatment utilization charac-
teristics of cocaine-using patients who presented to an
ED with a chief complaint of chest pain and who were
admitted to the CPOU for observation and treatment.
The ED serves as a ‘‘window of opportunity’’ for
identification and early intervention for substance
abusers.23 Therefore, this information regarding the
characteristics of cocaine users who present to the ED
with chest pain may aid in the development of ED-
based intervention protocols. In addition to providing
basic descriptive information about the characteristics
of these patients, this report also contrasts subgroups
of patients based on the presence of a substance use
diagnosis in the three months just before ED admis-
sion.
METHODS
Study Design. This study used a consecutive cohort
design. It was approved by the investigators’ in-
stitutional review boards.
Study Setting and Population. This study was
conducted at an urban, university-affiliated Level I
trauma center with an annual ED census of approx-
imately 75,000 patients per year. Patients presenting to
an ED CPOU with chest pain and recent cocaine use
were included.
CPOU Protocol. The institutional standard of care
where the study was conducted requires that patients
younger than 60 years of age who receive a workup
for potential acute coronary syndrome (ACS) also
undergo urine toxicologic screening for cocaine me-
tabolites (Synchron LX Systems, Fullerton, CA). A
detailed description of the CPOU protocol has pre-
viously been reported.24 Briefly, a cardiac troponin I
level (Access Accu TnI; Beckman Coulter, Fullerton,
CA) was measured at presentation and at three, six,
and nine hours. The threshold level of 0.5 ng/dL was
the institutional cutoff criteria. Cocaine use was
confirmed with toxicologic-positive urine screening
for cocaine metabolites (Synchron LX Systems). The
relative sensitivity (95%) and specificity (100%) of the
urine cocaine metabolite assay are excellent (Synchron
LX Systems).25
Sample Recruitment. To maximize patient recruit-
ment, members of the research staff were present in
the ED CPOU between 8 AM and 10 PM seven days per
week. The rationale for not deploying staff to recruit
patients during the midnight shift was based on
results from our pilot work indicating that patients
on this shift were generally sleeping and could not be
awakened to complete baseline assessments. Further,
because the institutional standard adopted by this ED
includes provisions for a nine-hour monitoring period
to assess low- to intermediate-risk patients with chest
pain (e.g., not at high risk for ACS) in the CPOU,
eligible patients often could be recruited by staff the
following morning. We used a two-phase enrollment
procedure.
Phase 1: Initial Screening. All consecutive patients
aged 18–60 years in the CPOU were initially considered
eligible for the study and approached by research staff
to participate in the screening during the recruitment
period (June 1, 2002, to February 29, 2004). Research
staff reviewed ED logs to identify CPOU patients to
participate in the screening. Research staff maintained
daily logs documenting the classification of potential
patients as either approached for the study and sub-
sequently screened, refused, or missed (e.g., not ap-
proached before leaving the ED). Each week, the field
supervisor conducted a quality review of the logs to
verify that every patient entering the ED with chest
pain was accounted for in the data.
For the initial screening, research staff obtained
written informed consent to view patient medical
records for determination of study eligibility. As an
incentive for the screening phase, patients who pro-
vided written informed consent to allow research staff
to review their medical records could choose a $1 item
from a gift basket containing items from a local ‘‘dollar’’
store (e.g., lotion, tape measure, flashlight, storage
containers). A research social worker reviewed con-
senting participants’ charts and documented the in-
clusion/exclusion criteria to determine eligibility for
the main study.
Inclusion Criteria. Inclusion criteria included age
18–60 years and a positive toxicologic urine screen
for cocaine or, if urine screen results were incomplete
or unavailable, physician documentation in the med-
ical chart indicating that the patient was treated for
cocaine-related chest pain and patient self-reported
cocaine use.
Exclusion Criteria. Because the study was focused on
the CPOU, high-risk patients were ineligible and were
defined as those admitted to the critical care unit or
telemetry unit; patients with an initial electrocardio-
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gram suggestive of ischemia, AMI, or ST-segment
elevation or depression of 1 mm or more that
persisted for at least 1 minute; elevated serum levels
of cardiac markers; recurrent ischemic chest pain;
a history of AMI or coronary artery bypass surgery;
hemodynamic instability; receiving anticoagulant
therapy in the ED (e.g., heparin, enoxaparin); or
receiving intravenous vasoactive medications (nitro-
glycerine, nitroprusside). Patients were also ineligible
for the study if they did not undergo a cardiac
workup for an ACS (e.g., local trauma, radiographic
abnormalities, or other clearly noncardiac causes) or if
they were pregnant, unable to provide informed
consent (e.g., unconscious, incarcerated, or did not
comprehend the English language), or acutely sui-
cidal (resulting in constant presence of designated
hospital staff, agitation, or violence while in the ED
requiring restraint or hospital security monitoring).
Phase 2: Main Study Enrollment. Subjects who par-
ticipated in the screening phase, met inclusion crite-
ria, and did not meet any exclusion criteria were
approached to participate in phase 2. Patients with
negative urine drug screens for cocaine were not
approached to participate in the study. After signing
a written consent form, a two-hour baseline interview
was conducted by trained research staff during the
patient’s CPOU stay and included questions about
demographics, substance use history, and mental
health (see Measures). After completing the baseline
assessment, all study participants were given referral
information for local substance abuse treatment ser-
vices and human immunodeficiency virus testing. Re-
muneration for the baseline assessment was a $25 gift
certificate to a local retailer (e.g., Wal-Mart, Target).
Measures. The baseline assessment contained a vari-
ety of measures, including the Substance Abuse Out-
comes Module (SAOM),26,27 the Brief Symptom
Inventory (BSI) to assess general psychological dis-
tress,28 and the Patient Health Questionnaire (PHQ-9)
to assess depression symptomatology.29,30
The SAOM is designed for evaluation of substance
abuse treatment outcomes (http://www.netoutcomes.
net) and measures Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition (DSM-IV) sub-
stance use disorders,31 a variety of key prognostic
factors for treatment outcome, and outcome domains.
For the current study, the SAOM was used to measure
basic demographic information, including age, gen-
der, race, marital status, education, and employment
status as well as information on lifetime and recent
(past three months) substance use diagnoses, sub-
stance abuse treatment history, antisocial personality
disorder, and substance-related consequences.32
The SAOM takes approximately 30 minutes to
complete and was administered by trained research
assistants. The SAOM has undergone extensive re-
liability and validity examinations and demonstrates
reasonable reliability (internal reliability, coefficient a,
0.58–0.90; test–retest reliability, 0.56–0.99) and validity
(concurrent validity generally 0.5–0.8; predictive val-
idity, 0.5–0.9).33 Concurrent validity for the SAOM
was based on longer key instruments such as a struc-
tured diagnostic interview for substance use disor-
ders, the Composite International Diagnostic
Interview—Substance Abuse Module (CIDI-SAM),34
and the Addiction Severity Index.35 The SAOM has
shown 90%–93% agreement with the CIDI-SAM on
DSM-IV substance use diagnosis (present/absent).33
The SAOM measures substance-related consequen-
ces using a 15-item index derived from the Inventory
of Drug Use Consequences (InDUC-2R) instrument
designed to assess lifetime and recent drug and/or
alcohol use consequences.32 Specifically, five subscales
(three items each) assess physical, intrapersonal, in-
terpersonal, impulse control, and social consequences
of substance use.
Self-reported use of substance abuse treatment
services included lifetime and past-year use of formal
specialty treatment services and/or informal services
(e.g., self-help groups) as well as past-year report of
any mental health–related treatment or treatment for
depression.
The BSI28 was used to measure psychological dis-
tress and includes three subscales that are labeled de-
pression, anxiety, and the global severity index. The
BSI has demonstrated good test–retest reliability for
the subscales (reliabilities of 0.68–0.91), high internal
consistency ratings (coefficient a of 0.71–0.85), and
sensitivity to change.28 In addition, the PHQ-929,30
was used as a more detailed examination of de-
pression severity and symptomatology. The PHQ-9
scores each of the nine DSM-IV criteria for depression
as zero (not at all) to three (nearly every day).
Substantial symptoms of depression are indicated by
PHQ-9 scores .12. The PHQ-9 has 94% specificity
and 99% sensitivity for current major depressive
disorder in a primary care population.29,30 PHQ-9
total scores range from zero to 27 with severity
defined as follows: none (0–5), mild (6–10), moderate
(11–15), major (16–20), severe (211).
Staff Training. Training for research staff was pro-
vided, including mock sessions in administration of the
interview instruments with the field coordinator and
observation of interviews with patients until acceptable
competence with the interview was achieved. Periodic
retraining sessions to maintain the integrity of the
study protocol were also provided to research staff,
and reliability checks on interviewers included regular
review for out-of-range values and error reports that
were generated and reviewed with staff.
Data Analysis. Descriptive statistics were computed
for basic sociodemographic, service use, substance
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use, and psychological characteristics. Bivariate anal-
yses were computed to compare participants who met
criteria for either a DSM-IV substance abuse or
dependence diagnosis in the past three months with
those who did not meet these criteria; specifically,
analysis of variance was used for continuous mea-
sures and chi-square tests for categorical measures.
We chose to classify patients by diagnoses of sub-
stance use disorders in general, rather than by cocaine
use disorders specifically, in order to investigate their
entire addiction severity, which included alcohol and
marijuana abuse and dependence for many patients.
In fact, results were very similar when classifying
patients by substance use or cocaine disorders except
that differences were stronger for the former because
the ‘‘no cocaine diagnosis’’ group included individu-
als with alcohol or other substance use disorders. SAS
software (version 8.2; SAS Institute, Inc., Cary, NC)
was used for statistical analyses.
RESULTS
Figure 1 provides a summary of the study recruitment
efforts for phase 1 and phase 2. Of 1,437 total patients
with chest pain eligible for phase 1 (which involved
consent for research staff to view their medical
record), 94% (n = 1,343) agreed to participate, 4%
(n = 63) refused, and 2% (n = 31) were missed (e.g.,
admitted and discharged during the shift not covered
or staff simply missed subject). The primary reasons
noted by research staff for patient refusal to partici-
pate in phase 1 were due to patient concerns about
confidentiality or invasion of privacy (n = 22), the
patient simply did not want to participate (n = 14),
and reasons related to severe pain, fatigue, or emo-
tional stress (n = 16) or other reasons (n = 11). Our
local institutional review board did not permit review
of medical records for patients who did not consent to
participate in phase 1 of the study. Therefore, it was
not possible to determine whether subjects refusing to
participate in phase 1 of the consent process differed
from consenting patients.
Of the 1,343 who agreed to participate in phase 1,
urine cocaine screens were completed on 1,192 (89%),
of which 205 (18%) were positive and thus eligible to
participate in phase 2 of the study. Fifty-two cocaine-
positive patients were deemed ineligible due to
receiving anticoagulant therapy or intravenous vaso-
Figure 1. Recruitment of participants in the chest pain observation unit for the cocaine chest pain study between June 1, 2002, and
February 29, 2004.
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active medications (n = 27), evidence indicating pre-
vious history of myocardial infarction or coronary
artery bypass grafting (n = 10), or other reasons
(n = 15). Urine cocaine screens were incomplete for
an additional six patients who were also considered
eligible for phase 2 because they had reported recent
cocaine use that was corroborated by physician
documentation in their medical record indicating
they were being treated for cocaine-related chest
pain. Of these 211 individuals with recent cocaine
use, 69% agreed to participate (n = 145), 19% refused,
and 12% were missed by recruitment staff for various
reasons (e.g., occupied with other subjects, patient
discharged) (see Figure 1). The most common reasons
for refusal to participate in phase 2 (n = 41) were
related to the length of the interview; the patient being
too ill, weak or tired; failure to schedule or keep an
appointment for the interview; or patient denial of
cocaine use despite a positive urine laboratory result.
Sociodemographic and Clinical Characteristics.
Table 1 presents the sociodemographic, clinical, and
service use characteristics for the total sample (e.g.,
phase 2 participants).
The majority of the sample (86%; n = 124) met the
American Psychiatric Association’s DSM-IV criteria
for a lifetime diagnosis of substance abuse (8%; n = 12)
or dependence, with most (77%; n = 121) meeting
criteria for dependence (Table 1). One half of the total
sample (50%; n = 72) met criteria for a recent sub-
stance use diagnosis in the past three months. Among
those with a recent substance dependence diagnosis
(n = 59), the sample was fairly evenly divided among
those with cocaine dependence (28%; n = 40) and
alcohol dependence (10%; n = 15) while four subjects
(3%) met criteria for other drug dependence (mari-
juana was the other illicit drug used most often).
Among the 13 patients (9%) who met criteria for past
three-month substance abuse diagnosis, seven (54%)
met criteria for alcohol abuse and six (46%) met
criteria for cocaine abuse.
As shown in Table 1, the study participants overall
reported an average of 7.6 days using crack/cocaine
in the past month before ED presentation (median,
4 days). More than one third of the sample reported
very infrequent use of cocaine during the previous 28
days (e.g., 1–2 days, n = 58, 42%), 41 (30%) reported
cocaine use ranging from three to ten days, 30 (22%)
reported cocaine use ranging from 11 to 28 days, and
nine (7%) reported daily use of cocaine in the past 28
days (data not shown). Seven participants, despite
a positive urine toxicology screen for cocaine, refused
to provide data on how many days they had used
cocaine in the past 28 days. Recent marijuana and
alcohol use were also commonly reported by study
participants (only one participant refused to answer
frequency items about marijuana). Overall, the sample
had moderate levels of depression from the PHQ-9
total scores and relatively poor psychological func-
tioning as indicated by the BSI scales, and their
InDUC-2R scores indicated frequent social conse-
quences resulting from substance use.
Correlates of Recent DSM-IV Substance Use
Diagnosis. Comparisons among the substance use
diagnostic groups defined by past three-month di-
agnoses of substance dependence and abuse and
those with no diagnosis found no significant differ-
ences in age, gender, race, marital status, education,
TABLE 1. Sociodemographic, Service Use,
Substance Use, and Psychological Characteristics
of Total Sample (n = 145)
Characteristics
Male (%) 97 (67)
African-American (%) 111 (77)
Married/living together (%) 37 (26)
High school educated (%) 89 (61)





DSM-IV substance use diagnoses (%)
Lifetime substance abuse 12 (8)
Lifetime substance dependence 112 (77)
Cocaine abuse (past 3 months) 6 (4)
Cocaine dependence (past 3 months) 40 (28)
Alcohol abuse (past 3 months) 7 (5)
Alcohol dependence (past 3 months) 15 (10)
Other drug dependence (past 3 months) 4 (3)
Lifetime substance abuse treatment (formal) (%) 79 (54)
Formal or informal past-year substance abuse
treatment (%)y 30 (22)
Past-year mental health treatment (%) 28 (19)
Past-year depression treatment (%) 24 (17)
Needed or wanted but did not get substance
abuse treatment in past year (%) 57 (39)
Antisocial personality disorder (%) 45 (29)
Mean age (SD) 39 (8.9)
Mean substance use frequency (past 4 weeks)
(SD)
Days using crack/cocainez 7.6 (8.2)
Days using marijuana§ 6.5 (9.2)
Days drinking alcohol 11.4 (10.4)
Mean depression symptom severity (SD)
Patient Health Questionnaire 9 total score 10.4 (7.9)
Mean Brief Symptom Inventory scores (SD)
Depression 7.1 (6.9)
Anxiety 5.7 (5.5)
Global severity index 48.5 (42.7)






Social responsibility 3.9 (3.0)
*Thirty five participants did not respond to this item.
yEight participants did not respond to this item.
zSeven participants did not respond to this item.
§One participant did not respond to this item.
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employment, and past-year mental health or depres-
sion treatment (see Table 2). Significant associations
were found between substance use diagnoses and
income, lifetime substance abuse treatment, formal or
informal past-year substance use treatment, and self-
reported need or desire for substance abuse treatment
but lack of getting it in the past year. Not surprisingly,
individuals with recent diagnoses were more likely
to have received lifetime and recent substance abuse
treatment.
Table 3 shows comparisons by recent DSM-IV
substance use diagnosis for substance use and mental
health characteristics. Significantly associated with
the presence of a substance dependence diagnosis
were greater frequency of cocaine, marijuana, and
alcohol use; greater depression symptom severity
assessed by the PHQ-9; and greater psychological
distress according to the BSI depression, anxiety, and
global scores (where higher scores indicate more
problems). InDUC-2R measures of physical, interper-
sonal, intrapersonal, impulse, and social responsibil-
ity consequences were significantly greater for those
with substance use diagnoses. Antisocial personality
disorder was also significantly associated with the
presence of a substance use disorder diagnosis.
DISCUSSION
Although substance use is relatively frequent among
patients presenting to urban public EDs,1,36 very little
is known about the spectrum of drug use or extent of
psychiatric disorders and psychological problems in
these nontreatment settings. We report findings from
a study of ED patients admitted to a CPOU who were
at low to intermediate risk for ACS and had recently
used cocaine before their ED presentation for chest
pain. We chose to sample a homogeneous, low to
moderate ACS risk population observed and dis-
charged from the CPOU in order to gain a better
understanding of the sociodemographic and clinical
characteristics of cocaine users seen and discharged
entirely from an ED setting. For these patients, the ED
is possibly their only contact with health care pro-
viders who have an opportunity to reinforce the
dangers of continued cocaine use, and emergency
physicians cannot rely on inpatient services to address
and intervene regarding substance use. Indeed, with
continued cocaine use, this population of patients is at
high risk for progression of cardiac disease,22 and
most cocaine users with chest pain have few tradi-
tional risk factors for ACS other than smoking. Thus,
secondary prevention of cardiac disease in this pop-
ulation should focus primarily on cessation of cocaine
use. Moreover, understanding the spectrum of drug
use and associated problems in these patients can
greatly assist the clinician in determining the need for
subsequent substance abuse treatment as well as
ongoing cardiac risk.
Our study found a great deal of demographic and
clinical heterogeneity in this population of cocaine
users. The majority of our patients were high school
educated, almost one half were employed, and nearly
one fourth had undergone substance abuse treatment
in the past year, suggesting a potentially higher
TABLE 2. Sociodemographic and Service Use Correlates of Recent DSM-IV Substance Use Diagnosis
No DSM-IV Substance
Diagnosis (n = 73; 50%)
DSM-IV Substance
Abuse (n = 13; 9%)
DSM-IV Substance
Dependence (n = 59; 41%)
Mean age (6SD)* 40.2 (9.8) 38 (7.2) 37.6 (7.9)
Male* 46 (63) 8 (62) 43 (73)
African-American* 57 (78) 8 (62) 46 (78)
Married/living together* 17 (23) 4 (31) 16 (27)
High school educated* 41 (56) 7 (54) 41 (69)
Employed* 32 (43) 11 (85) 23 (39)
Annual incomey
,$10,000 21 (40) 1 (10) 10 (21)
$10,000–19,999 22 (42) 3 (30) 17 (36)
>$20,000 10 (19) 6 (60) 20 (43)
Lifetime substance abuse treatment (formal)z 33 (45) 9 (69) 37 (63)
Formal or informal past-year substance abuse
treatment§ 12 (17) 10 (0) 18 (32)
Past-year mental health treatment* 16 (22) 2 (15) 10 (17)
Past-year depression treatment* 13 (18) 2 (15) 9 (15)
Needed or wanted but did not get substance
abuse treatment in past yeark 16 (22) 7 (54) 34 (58)
All values are expressed as n (%).
*No significant difference between substance use diagnosis groups (p > 0.05).
yx
2 = 7.26, df = 1, p , 0.0071.
zx
2 = 4.14, df = 1, p , 0.0418.
§x2 = 3.99, df = 1, p , 0.0457.
kx2 = 17.6, df = 1, p , 0.0001.
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functioning cohort than may have been previously
described. Although medically these patients are
grouped together into ‘‘chest pain due to cocaine
use’’ by study design, they were not homogeneous in
terms of substance use consequences, psychological
distress, or depressive symptomatology or treatment
history. One half of the sample met criteria for sub-
stance abuse or dependence in the past three months,
primarily cocaine or alcohol dependence; on the other
hand, a substantial proportion surprisingly did not
meet abuse or dependence criteria and reported
infrequent cocaine use. The anecdotal clinical percep-
tion of cocaine users who present to urban EDs with
chest pain is that they are ‘‘addicts‘‘ or heavy users.
This perception may be in part due to clinical stereo-
typing where clinicians are more likely to remember
and classify cocaine/crack users as frequent recidi-
vists or ‘‘frequent flyers’’ who may overrepresent the
more severe end of the spectrum of cocaine use.37,38
Weber et al. have recommended that institutions
implementing brief observation periods for patients
who present to the ED with cocaine-associated chest
pain also incorporate strategies for encouraging sub-
stance abuse treatment due to increased likelihood of
nonfatal myocardial infarction in those who continue
to use cocaine.22 Occurrence of chest pain severe
enough to bring a cocaine user to the ED could
provide the opportunity for brief interventions to
increase problem recognition among cocaine-using
individuals and increase follow-through with treat-
ment referral.23,39–41 The concept of intervening for
risky behaviors among ED patients, in particular
alcohol problems, has been shown to be reasonable
and effective.39,40 One step to identifying the cocaine-
using patient with chest pain who may greatly benefit
from substance use treatment is to discuss the extent
of recent cocaine and alcohol use, both of which were
strongly associated with recent substance abuse di-
agnoses in our sample. About one half of patients
meeting abuse or dependence criteria reported they
needed or wanted treatment. ED staff might consider
counseling patients who report very frequent recent
cocaine or alcohol use to seek assessment for possible
substance abuse treatment. However, all patients with
cocaine-associated chest pain should be advised to
refrain from cocaine use to prevent acceleration of
coronary disease.
We found that substance use consequences mea-
sured by the InDUC-2R were significantly more likely
to occur among those with DSM-IV substance use
disorders, and indeed the scores for patients with
recent dependence are similar to those reported in
treatment samples.33 This finding corroborates di-
agnoses derived by self-report on the SAOM and is
not surprising given that the DSM-IV criteria also
measure both physical and psychological consequen-
















Substance use frequency (past 4 weeks)
Days using crack/cocaine* 5.2 (6.4) 6.9 (8.1) 10.6 (9.3) Dependence > No SUD
Days using marijuana*,y 5.1 (8.3) 2.4 (4.1) 9.1 (10.4) Dependence > No SUD
Dependence > Abuse
Days drinking alcohol* 9.6 (10.1) 11.0 (7.5) 13.7 (10.9) Dependence > No SUD
Depression symptom severity
Patient Health Questionnaire 9 total score* 8.3 (7.5) 11.4 (7.6) 12.6 (8.1) Dependence > No SUD
Brief Symptom Inventory scores
Depression* 5.3 (5.2) 7.3 (6.7) 9.4 (7.6) Dependence > No SUD
Anxiety* 4.6 (5.3) 6.2 (4.9) 6.9 (5.7) Dependence > No SUD
Global severity index* 37.5 (39.1) 48.1 (32.8) 62.1 (45.5) Dependence > No SUD
Inventory of Drug Use Consequences scales
Physical*,y 2.1 (2.5) 2.5 (1.9) 4.8 (2.5) Dependence > No SUD
Dependence > Abuse
Interpersonal*,y 1.8 (2.7) 2.9 (1.8) 4.7 (3.1) Dependence > No SUD
Dependence > Abuse
Intrapersonal*,y 2.4 (2.7) 3.9 (2.2) 6.1 (2.5) Dependence > No SUD
Dependence > Abuse
Impulse*,y 1.3 (2.0) 2.4 (1.2) 3.6 (2.2) Dependence > No SUD
Dependence > Abuse
Social responsibility*,y 2.4 (2.6) 3.7 (1.8) 5.8 (2.6) Dependence > No SUD
Dependence > Abuse
Antisocial personality disorder, n (%) 12 (16) 4 (31) 25 (42) x2 = 10.78, df = 1, p , 0.01
All values are expressed as mean (SD) unless otherwise noted.
SUD = substance use disorder diagnosis.
*p , 0.05, substance dependence vs. no diagnosis, post hoc test for group differences.
yp , 0.05, substance abuse vs. substance dependence, post hoc test for group differences.
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ces of substance use.31 What we do not know is
whether physical and psychological consequences of
greater substance use, such as those in the DSM-IV or
the InDUC-2R, are risk factors for subsequent ACS,
and longitudinal data are needed to determine this
issue. Interestingly, previous work by Hollander et al.5
found that demographic and clinical factors, includ-
ing the frequency of cocaine use, were of little
assistance to physicians in identifying/discriminating
which patients with cocaine-associated chest pain are
at very low risk for myocardial infarction.
About one half of our sample reported moderate to
severe depressive symptomatology on the PHQ-9.29,30
BSI scores of the sample are higher than general
population norms and are comparable to norms for
a large outpatient psychiatry sample.42 Depressive
symptomatology can be caused by intoxication and
withdrawal from drugs or alcohol as well as by
the psychological sequelae of substance use disor-
ders31,43–45; thus, any depressive symptoms observed
in our sample at the time of completing the interviews
may be due to a variety of reasons. Even though we
did not make diagnoses of major depressive disorder
because of the potential confounding effect of cocaine
withdrawal, it is clear that depressive symptom-
atology is higher among those with substance use
disorder diagnoses and may be a function of greater
frequency of cocaine use. This issue warrants further
investigation. In a non–cocaine use population, the
PHQ-9 scores we observed for those with substance
dependence diagnoses would be indicative of a major
depressive disorder. Only about 20% of the sample
reported seeking treatment for depression or other
mental health issues in the past year.
LIMITATIONS
One limitation of this study is that the protocol, as
required by the local institutional review board, did
not allow for viewing medical records of patients
who did not consent to participate in phase 1 of the
study; thus, it was not possible to examine whether
they were different from consenting patients. Fur-
thermore, all of our data, including reports of sub-
stance use frequency, are self-report, although all but
six of our sample had a positive urine screen for
recent cocaine use. It is possible that patients in this
study underreported the frequency of their cocaine
or other drug use due to embarrassment, fear of legal
repercussions, desire to minimize their problems,
and/or issues related to talking with a stranger
about these issues. Thus, our findings may actually
reflect an underestimate of the extent of substance
use severity in this sample. Nonetheless, a strength
of the data presented in this study is that it
represents an almost complete and consecutive
enumeration of patients presenting to a CPOU with
chest pain and recent cocaine use.
CONCLUSIONS
Patients with chest pain in the ED who have recently
used cocaine represent a diverse spectrum of sub-
stance abuse. The occurrence of chest pain severe
enough to bring a cocaine user to the ED could
provide the opportunity for cocaine-using individuals
to recognize the adverse and potentially life-threaten-
ing consequences of drug use and to either seek
formal or informal treatment or to reduce or eliminate
their cocaine use without treatment. The costs associ-
ated with ED service use and cocaine-related chest
pain have been extraordinary.5 The ED serves a unique
role in the health care system and many patients
who use EDs, especially inner-city EDs, do not have
a primary care physician, do not routinely receive
medical care other than in the ED setting, are minority
patients, and/or are patients of lower socioeconomic
status.46–49 Thus, patients who are reliant on such
emergency care may be in greater need of prompt,
seamless referral and follow-up care to interrupt the
downward spiral associated with continued cocaine
use and its medical and psychological complications.
The authors thank Shanti Tripathi (statistical analyst), Debbie
Hodges (database manager), and Shannon Watson (administrative
support).
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